 |
The Journal of Neuroscience, March 23, 2005, 25(12):3032-3040; doi:10.1523/JNEUROSCI.4225-04.2005
Previous Article | Next Article 
Neurobiology of Disease
A Diet Enriched with the Omega-3 Fatty Acid Docosahexaenoic Acid Reduces Amyloid Burden in an Aged Alzheimer Mouse Model
Giselle P. Lim,1,3
Frédéric Calon,1,3
Takashi Morihara,1,3
Fusheng Yang,1,3
Bruce Teter,1,3
Oliver Ubeda,1,3
Norman Salem, Jr,5
Sally A. Frautschy,1,3,2,4 and
Greg M. Cole1,3,2,4
Departments of 1Medicine and 2Neurology, University of California Los Angeles, Los Angeles, California 90095, 3Veterans Affairs Greater Los Angeles Healthcare System and 4Geriatric Research Educational Clinical Center, North Hills, California 91343, and 5Section of Nutritional Neuroscience, Laboratory of Membrane Biochemistry and Biophysics, Division of Intramural Clinical and Biological Research, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Rockville, Maryland 20852
Epidemiological studies suggest that increased intake of the omega-3 (n-3) polyunsaturated fatty acid (PUFA) docosahexaenoic acid (DHA) is associated with reduced risk of Alzheimer's disease (AD). DHA levels are lower in serum and brains of AD patients, which could result from low dietary intake and/or PUFA oxidation. Because effects of DHA on Alzheimer pathogenesis, particularly on amyloidosis, are unknown, we used the APPsw (Tg2576) transgenic mouse model to evaluate the impact of dietary DHA on amyloid precursor protein (APP) processing and amyloid burden. Aged animals (17-19 months old) were placed in one of three groups until 22.5 months of age: control (0.09% DHA), low-DHA (0%), or high-DHA (0.6%) chow. -Amyloid (A ) ELISA of the detergent-insoluble extract of cortical homogenates showed that DHA-enriched diets significantly reduced total A by >70% when compared with low-DHA or control chow diets. Dietary DHA also decreased A 42 levels below those seen with control chow. Image analysis of brain sections with an antibody against A (amino acids 1-13) revealed that overall plaque burden was significantly reduced by 40.3%, with the largest reductions (40-50%) in the hippocampus and parietal cortex. DHA modulated APP processing by decreasing both - and -APP C-terminal fragment products and full-length APP. BACE1 ( -secretase activity of the -site APP-cleaving enzyme), ApoE (apolipoprotein E), and transthyretin gene expression were unchanged with the high-DHA diet. Together, these results suggest that dietary DHA could be protective against -amyloid production, accumulation, and potential downstream toxicity.
Key words: DHA; polyunsaturated fatty acid; A ; APP; secretase; Alzheimer
Received Oct 11, 2004;
revised February 8, 2005;
accepted February 9, 2005.
This article has been cited by other articles:

|
 |

|
 |
 
J. Joseph, G. Cole, E. Head, and D. Ingram
Nutrition, Brain Aging, and Neurodegeneration
J. Neurosci.,
October 14, 2009;
29(41):
12795 - 12801.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Q.-L. Ma, F. Yang, E. R. Rosario, O. J. Ubeda, W. Beech, D. J. Gant, P. P. Chen, B. Hudspeth, C. Chen, Y. Zhao, et al.
{beta}-Amyloid Oligomers Induce Phosphorylation of Tau and Inactivation of Insulin Receptor Substrate via c-Jun N-Terminal Kinase Signaling: Suppression by Omega-3 Fatty Acids and Curcumin
J. Neurosci.,
July 15, 2009;
29(28):
9078 - 9089.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. W. Fetterman Jr. and M. M. Zdanowicz
Therapeutic potential of n-3 polyunsaturated fatty acids in disease
Am. J. Health Syst. Pharm.,
July 1, 2009;
66(13):
1169 - 1179.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Umezawa, K. Higuchi, M. Mori, T. Matushita, and M. Hosokawa
Effect of Dietary Unsaturated Fatty Acids on Senile Amyloidosis in Senescence-Accelerated Mice
J Gerontol A Biol Sci Med Sci,
June 1, 2009;
64A(6):
646 - 652.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. S. Harris, D. Mozaffarian, M. Lefevre, C. D. Toner, J. Colombo, S. C. Cunnane, J. M. Holden, D. M. Klurfeld, M. C. Morris, and J. Whelan
Towards Establishing Dietary Reference Intakes for Eicosapentaenoic and Docosahexaenoic Acids
J. Nutr.,
April 1, 2009;
139(4):
804S - 819S.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
I. Torres-Aleman
Mouse Models of Alzheimer's Dementia: Current Concepts and New Trends
Endocrinology,
December 1, 2008;
149(12):
5952 - 5957.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. L. Petursdottir, S. A. Farr, J. E. Morley, W. A. Banks, and G. V. Skuladottir
Effect of Dietary n-3 Polyunsaturated Fatty Acids on Brain Lipid Fatty Acid Composition, Learning Ability, and Memory of Senescence-Accelerated Mouse
J. Gerontol. A Biol. Sci. Med. Sci.,
November 1, 2008;
63(11):
1153 - 1160.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Delbosc, M. Glorian, A.-S. Le Port, G. Bereziat, M. Andreani, and I. Limon
The Benefit of Docosahexanoic Acid on the Migration of Vascular Smooth Muscle Cells Is Partially Dependent on Notch Regulation of MMP-2/-9
Am. J. Pathol.,
May 1, 2008;
172(5):
1430 - 1440.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Bousquet, M. Saint-Pierre, C. Julien, N. Salem Jr., F. Cicchetti, and F. Calon
Beneficial effects of dietary omega-3 polyunsaturated fatty acid on toxin-induced neuronal degeneration in an animal model of Parkinson's disease
FASEB J,
April 1, 2008;
22(4):
1213 - 1225.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Z. Ungvari, C. Parrado-Fernandez, A. Csiszar, and R. de Cabo
Mechanisms Underlying Caloric Restriction and Lifespan Regulation: Implications for Vascular Aging
Circ. Res.,
March 14, 2008;
102(5):
519 - 528.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Q.-L. Ma, B. Teter, O. J. Ubeda, T. Morihara, D. Dhoot, M. D. Nyby, M. L. Tuck, S. A. Frautschy, and G. M. Cole
Omega-3 Fatty Acid Docosahexaenoic Acid Increases SorLA/LR11, a Sorting Protein with Reduced Expression in Sporadic Alzheimer's Disease (AD): Relevance to AD Prevention
J. Neurosci.,
December 26, 2007;
27(52):
14299 - 14307.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Cherubini, C. Andres-Lacueva, A. Martin, F. Lauretani, A. D. Iorio, B. Bartali, A. Corsi, S. Bandinelli, M. P. Mattson, and L. Ferrucci
Low Plasma N-3 Fatty Acids and Dementia in Older Persons: The InCHIANTI Study
J. Gerontol. A Biol. Sci. Med. Sci.,
October 1, 2007;
62(10):
1120 - 1126.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. N. Green, H. Martinez-Coria, H. Khashwji, E. B. Hall, K. A. Yurko-Mauro, L. Ellis, and F. M. LaFerla
Dietary Docosahexaenoic Acid and Docosapentaenoic Acid Ameliorate Amyloid-{beta} and Tau Pathology via a Mechanism Involving Presenilin 1 Levels
J. Neurosci.,
April 18, 2007;
27(16):
4385 - 4395.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. M. Malm, H. Iivonen, G. Goldsteins, V. Keksa-Goldsteine, T. Ahtoniemi, K. Kanninen, A. Salminen, S. Auriola, T. Van Groen, H. Tanila, et al.
Pyrrolidine Dithiocarbamate Activates Akt and Improves Spatial Learning in APP/PS1 Mice without Affecting {beta}-Amyloid Burden
J. Neurosci.,
April 4, 2007;
27(14):
3712 - 3721.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. C. Morris
Docosahexaenoic Acid and Alzheimer Disease
Arch Neurol,
November 1, 2006;
63(11):
1527 - 1528.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. L. Masters and K. Beyreuther
Alzheimer's centennial legacy: prospects for rational therapeutic intervention targeting the A{beta} amyloid pathway
Brain,
November 1, 2006;
129(11):
2823 - 2839.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Freund-Levi, M. Eriksdotter-Jonhagen, T. Cederholm, H. Basun, G. Faxen-Irving, A. Garlind, I. Vedin, B. Vessby, L.-O. Wahlund, and J. Palmblad
{omega}-3 Fatty Acid Treatment in 174 Patients With Mild to Moderate Alzheimer Disease: OmegAD Study: A Randomized Double-blind Trial.
Arch Neurol,
October 1, 2006;
63(10):
1402 - 1408.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
V. Stenset, L. Johnsen, D. Kocot, A. Negaard, A. Skinningsrud, P. Gulbrandsen, A. Wallin, and T. Fladby
Associations between white matter lesions, cerebrovascular risk factors, and low CSF Abeta42.
Neurology,
September 12, 2006;
67(5):
830 - 833.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. A. Farooqui and L. A. Horrocks
Phospholipase A2-Generated Lipid Mediators in the Brain: The Good, the Bad, and the Ugly
Neuroscientist,
June 1, 2006;
12(3):
245 - 260.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
L. M Arterburn, E. B. Hall, and H. Oken
Distribution, interconversion, and dose response of n-3 fatty acids in humans
Am. J. Clinical Nutrition,
June 1, 2006;
83(6):
S1467 - 1476S.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Calon
Nonpatentable drugs and the cost of our ignorance.
Can. Med. Assoc. J.,
February 14, 2006;
174(4):
483 - 484.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. N. Serhan, K. Gotlinger, S. Hong, Y. Lu, J. Siegelman, T. Baer, R. Yang, S. P. Colgan, and N. A. Petasis
Anti-Inflammatory Actions of Neuroprotectin D1/Protectin D1 and Its Natural Stereoisomers: Assignments of Dihydroxy-Containing Docosatrienes
J. Immunol.,
February 1, 2006;
176(3):
1848 - 1859.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. T. Maloney, L. S. Minamide, A. W. Kinley, J. A. Boyle, and J. R. Bamburg
{beta}-Secretase-Cleaved Amyloid Precursor Protein Accumulates at Actin Inclusions Induced in Neurons by Stress or Amyloid {beta}: A Feedforward Mechanism for Alzheimer's Disease
J. Neurosci.,
December 7, 2005;
25(49):
11313 - 11321.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|

|